WO2004089359A1 - 骨密度減少の抑制または予防用組成物および飲食品 - Google Patents
骨密度減少の抑制または予防用組成物および飲食品 Download PDFInfo
- Publication number
- WO2004089359A1 WO2004089359A1 PCT/JP2004/005087 JP2004005087W WO2004089359A1 WO 2004089359 A1 WO2004089359 A1 WO 2004089359A1 JP 2004005087 W JP2004005087 W JP 2004005087W WO 2004089359 A1 WO2004089359 A1 WO 2004089359A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isoxanthohumol
- food
- drink
- hop
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 230000037182 bone density Effects 0.000 title claims abstract description 40
- 230000002265 prevention Effects 0.000 title claims abstract description 12
- 230000005764 inhibitory process Effects 0.000 title abstract description 4
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 claims abstract description 208
- YKGCBLWILMDSAV-SFHVURJKSA-N isoxanthohumol Chemical compound C1([C@H]2OC=3C(CC=C(C)C)=C(O)C=C(C=3C(=O)C2)OC)=CC=C(O)C=C1 YKGCBLWILMDSAV-SFHVURJKSA-N 0.000 claims abstract description 166
- 239000000284 extract Substances 0.000 claims abstract description 104
- 239000004615 ingredient Substances 0.000 claims abstract description 3
- 235000013305 food Nutrition 0.000 claims description 103
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 69
- 239000004480 active ingredient Substances 0.000 claims description 49
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 claims description 42
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 claims description 42
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 claims description 42
- 235000008209 xanthohumol Nutrition 0.000 claims description 42
- 208000001132 Osteoporosis Diseases 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 230000003405 preventing effect Effects 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 35
- 235000013361 beverage Nutrition 0.000 claims description 32
- 230000037396 body weight Effects 0.000 claims description 26
- 235000013616 tea Nutrition 0.000 claims description 24
- 239000002904 solvent Substances 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 18
- 238000006317 isomerization reaction Methods 0.000 claims description 16
- 238000000605 extraction Methods 0.000 claims description 15
- 235000019985 fermented beverage Nutrition 0.000 claims description 14
- 235000021107 fermented food Nutrition 0.000 claims description 13
- 210000000988 bone and bone Anatomy 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 6
- 239000011707 mineral Substances 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 235000013618 yogurt Nutrition 0.000 claims description 6
- 235000020124 milk-based beverage Nutrition 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 3
- 235000013339 cereals Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 61
- 238000002360 preparation method Methods 0.000 abstract description 26
- 229940011871 estrogen Drugs 0.000 abstract description 25
- 239000000262 estrogen Substances 0.000 abstract description 25
- 235000013405 beer Nutrition 0.000 description 54
- LPEPZZAVFJPLNZ-SFHVURJKSA-N sophoraflavanone B Chemical compound C1([C@@H]2CC(=O)C=3C(O)=CC(O)=C(C=3O2)CC=C(C)C)=CC=C(O)C=C1 LPEPZZAVFJPLNZ-SFHVURJKSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 244000269722 Thea sinensis Species 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 238000012360 testing method Methods 0.000 description 30
- 241000700159 Rattus Species 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 29
- YHWNASRGLKJRJJ-UHFFFAOYSA-N sophoraflavanone B Natural products C1C(=O)C2=C(O)C(CC=C(C)C)=C(O)C=C2OC1C1=CC=C(O)C=C1 YHWNASRGLKJRJJ-UHFFFAOYSA-N 0.000 description 23
- 230000002829 reductive effect Effects 0.000 description 21
- 239000000243 solution Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 239000000126 substance Substances 0.000 description 16
- 230000001076 estrogenic effect Effects 0.000 description 13
- 235000009569 green tea Nutrition 0.000 description 13
- 239000007788 liquid Substances 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 235000008694 Humulus lupulus Nutrition 0.000 description 11
- 239000012153 distilled water Substances 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 208000006386 Bone Resorption Diseases 0.000 description 9
- 240000005979 Hordeum vulgare Species 0.000 description 9
- 235000007340 Hordeum vulgare Nutrition 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000024279 bone resorption Effects 0.000 description 9
- 229960005309 estradiol Drugs 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 230000006872 improvement Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000019658 bitter taste Nutrition 0.000 description 6
- 238000009835 boiling Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 235000013336 milk Nutrition 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 210000004080 milk Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical group OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 229930193815 Isohumulone Natural products 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 206010067572 Oestrogenic effect Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- -1 butylene glycol Glycols Chemical class 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229910052791 calcium Inorganic materials 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 206010065687 Bone loss Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 230000001476 alcoholic effect Effects 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 229930182833 estradiol Natural products 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000020595 eating behavior Effects 0.000 description 3
- 230000004821 effect on bone Effects 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- PFRQBZFETXBLTP-RCIYGOBDSA-N 2-[(2e,6e,10e,14e,18e)-3,7,11,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaen-1-yl]-3-methyl-1,4-dihydronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-RCIYGOBDSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004373 Pullulan Substances 0.000 description 2
- 229920001218 Pullulan Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000006468 Thea sinensis Nutrition 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 229940037448 calcitonin preparations Drugs 0.000 description 2
- 210000000692 cap cell Anatomy 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000011850 desserts Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002212 flavone derivatives Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- QARXXMMQVDCYGZ-UHFFFAOYSA-N isohumulone Chemical compound CC(C)CC(=O)C1=C(O)C(O)(C(=O)CC=C(C)C)C(CC=C(C)C)C1=O QARXXMMQVDCYGZ-UHFFFAOYSA-N 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000009806 oophorectomy Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 235000019423 pullulan Nutrition 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FCERNNLMTCOKHX-UHFFFAOYSA-O 1,5-diphenyl-2H-tetrazol-1-ium Chemical compound C1=CC=CC=C1C1=[NH+]N=NN1C1=CC=CC=C1 FCERNNLMTCOKHX-UHFFFAOYSA-O 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 244000302899 Cassia mimosoides Species 0.000 description 1
- 235000014112 Cassia mimosoides Nutrition 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 102100027069 Odontogenic ameloblast-associated protein Human genes 0.000 description 1
- 101710091533 Odontogenic ameloblast-associated protein Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046782 Uterine enlargement Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019541 flavored milk drink Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229930186179 lupulin Natural products 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011457 non-pharmacological treatment Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000020333 oolong tea Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Definitions
- the present invention relates to a composition for suppressing or preventing a decrease in bone density, and a food or drink. More specifically, the present invention relates to a composition for preventing, treating or ameliorating osteoporosis, and a food or drink for preventing, treating or ameliorating osteoporosis.
- Osteoporosis is a disease characterized by low bone mass and disruption of the fine structure of bone tissue, which leads to increased bone fragility and an increased risk of fracture. Osteoporosis is a major health problem around the world, affecting one in three menopausal women and many elderly men and women. Fractures due to osteoporosis are the third largest cause of bedridden in Japan, for example, and one of the causes of increased medical expenses. In addition, the number of patients is expected to further increase with the progress of an aging society. Therefore, the development of a medicament for preventing, treating or ameliorating osteoporosis is extremely important.
- vitamin D preparations for example, vitamin D preparations, calcitonin preparations, estrogen preparations, Ivry flavone made, vitamin K 2 formulations, evening Npaku anabolic steroid preparation, and Bisuhosufone Single preparations are known.
- estrogen preparations are known to be effective in preventing or treating postmenopausal osteoporosis, but they cause irregular bleeding, breast cancer and uterine cancer. It is known that there are side effects such as an increase in raw risk.
- osteoporosis Treatment of osteoporosis with drugs often takes a long time, and various problems such as the occurrence of side effects due to prolonged administration cannot be ignored.
- drug-based treatment of osteoporosis is not intended for fundamental treatment, but for symptomatic treatment, such as inhibiting the progression of the disease.
- a prophylactic or therapeutic agent for osteoporosis that is safe and can be used on a daily basis is desired.
- it can be said that it is desirable from the viewpoint of safety to find ingredients that have the effect of preventing or treating osteoporosis from foods that have experienced eating.
- hop lupulin portion yellow granules formed at the base of the inner bract of the cone.
- Hope is also used as a folk medicine, and is known to have physiological effects such as sedative effects, sleep and sleep effects, appetite enhancement, stomachic effects, and diuretic effects.
- Hops have long been known to have estrogenic activity (eg, Munch. Med. Wschr. 95, 845 (1953)). Also, in 1999, 8-prenylnaringenin was isolated from hops as a female hormone active substance (J. Clinical Endocrinology & Metabolism 83 (6), 2249-2252 (1999)). Therefore, based on its activity, hop concentrates with significantly increased 8-prenylnaringenin content could be used for the prevention or treatment of postmenopausal osteoporosis, but there is a risk of causing side effects as with estrogen products .
- isohumulones isoarsenates
- isoxanthohumol isoxanthohumol.
- WO01 / 67614 discloses foods and beverages containing a plant-derived growth factor production enhancer, and mentions isoxanthohumol as the growth factor production enhancer. .
- this growth factor production enhancer has the effect of enhancing the production of hepatocyte enhancing factor (HGF) and nerve growth factor (NGF), and can be used for the treatment of diseases such as liver disorders, gastrointestinal disorders, pneumonia, and diabetes. It is also disclosed.
- HGF hepatocyte enhancing factor
- NGF nerve growth factor
- an isomerized hop-derived component contained in beer or the like has an excellent effect of suppressing or preventing a decrease in bone density. This effect was considered to be effective in preventing, treating or ameliorating osteoporosis. It has also been found that this effect is based on isoxanthohumol, and that the effect of isoxanthohumol is superior to that of its analogous compound xanthohumol. The present invention is based on these findings.
- an object of the present invention is to provide a composition and a food or drink used for preventing, treating or ameliorating osteoporosis, which have excellent safety and activity.
- composition for suppressing or preventing bone density loss comprises isoxanthohumol as an active ingredient.
- the composition according to the present invention may comprise an isomerized hop extract containing isoxanthohumol as an active ingredient.
- the composition for preventing, treating or ameliorating osteoporosis according to the present invention comprises isoxanthohumol as an active ingredient.
- the composition for preventing, treating or improving osteoporosis according to the present invention comprises an isomerized hop extract containing isoxanthohumol as an active ingredient.
- the food or drink for suppressing or preventing bone density loss according to the present invention comprises isoxanthohumol or an isomerized hop extract containing isoxanthohumol.
- the non-cereal-hop fermented food or drink according to the present invention comprises isoxanthohumol as an active ingredient in an amount such that the daily adult intake of isoxanthohumol is 0.003 to 0.5 mg / kg body weight. Things.
- the non-animal-hop fermented food or drink according to the present invention comprises isoxanthohumol in an amount such that the isoxanthohumol intake per serving is 0.2 to 3 O mg. It comprises tofumol as an active ingredient.
- the active ingredient of the composition or food or drink according to the present invention has an excellent effect of suppressing or preventing a decrease in bone density, and further has an effect of increasing bone density. Is also expected.
- This active ingredient is contained in beer and the like which has been consumed as food and drink for many years. Therefore, the composition or food or drink according to the present invention has little side effects even if the patient or a person who wants to prevent osteoporosis takes or eats for a long time, and is excellent in safety. Further, the composition or the food or drink according to the present invention does not show an estrogenic effect on immature rats even when the dose is 1000 times or more the dose expected to achieve the intended effect.
- the prevention, treatment or treatment of osteoporosis while avoiding the side effects due to estrogen action such as the case of estrogen preparations, for example, the risk of irregular bleeding, breast cancer and uterine cancer are increased. Excellent effects on improvement can be obtained.
- FIG. 1 is a graph showing the results of Test 2 of the example.
- the graph shows the estrogenic activity of isoxanthohumol and 8-prenylnaringenin as measured by MCF-7 cell growth.
- IXH represents isoxanthohumol
- 8PN represents 8-prenylnaringenin
- E 2 represents 17? -Estradiol.
- FIG. 2 is a graph showing the results of Test 3-a of the example.
- the graph shows the results of examining the in vivo estrogenic effect of isoxanthohumol and 8-prenylnaringenin on young rats.
- IXH represents isoxanthohumol
- 8PN represents 8-prenylnaringenin
- E2 represents 17-estradiol.
- FIG. 3 is a graph showing the results of Test 3-b of the example.
- the graph shows the results of examining the in vivo estrogenic effects of isoxanthohumol, 8-prenylnaringenin, and beads on ovariectomized rats.
- IXH represents isoxanthohumol
- 8PN represents 8-prenylnaringenin. Or means P ⁇ 0.001.
- FIG. 4 is a graph showing the results of Test 3-b of the example. The graph shows the results of examining the in vivo estrogenic effects of isoxanthohumol and beer on ovariectomized rats.
- IXH represents isoxanthohumol
- E2 represents 17-estradiol.
- *** means P ⁇ 0.001.
- FIG. 5 is a graph showing the results of Test 4 of the example. The graph shows the results of examining the effect of isoxanthohumol, 8-prenylnaringenin, and beer on bone density reduction in ovariectomized rats.
- IXH represents isoxanthohumol
- 8PN represents 8-prenylnaringenin. * Means P ⁇ 0.05 and *** means P ⁇ 0.001.
- FIG. 6 is a graph showing the results of Test 4 of the example.
- the graph shows the results of examining the effect of isoxanthohumol, xanthohumol, isoacid, and beer on bone density reduction in ovariectomized rats.
- IXH represents isoxanthohumol
- XNT represents xanthohumol
- E2 represents 17-estradiol.
- FIG. 7 is a graph showing the results of Test 5 of the example.
- the graph shows the results obtained by examining the effect of barley tea to which isoxanthohumol was added on ovariectomy rats to suppress bone density loss.
- OmgZL represents barley tea to which isoxanthohumol was not added, and 2 mg / Ls 10 mg / L and 50 mg / L were barley tea to which isoxanthohumol was added.
- * means ⁇ ⁇ 0.05, ⁇ ⁇ 0.01, and ⁇ ⁇ 0.001, and no isoxanthohumol was added.
- # means ⁇ ⁇ 0. 05, and means ⁇ ⁇ 0.01.
- FIG. 8 is a graph showing the results of Test 5 of the example.
- the graph shows the results of examining the effect of green tea to which isoxanthohumol was added on ovariectomized rats to inhibit bone density loss.
- OmgZL represents green tea to which isoxanthohumol was not added
- 1 Omg / L represents green tea to which isoxanthohumol was added
- its isoxanthohumol concentration was 1 OmgZL
- E2 was 17 5- represents estradiol.
- * means p ⁇ 0.05, p ⁇ 0.01, and p ⁇ 0.001, and no isoxanthohumol was added.
- # means p ⁇ 0. 05 and ## means p ⁇ 0.01.
- composition and the food or drink according to the present invention comprise isoxanthohumol or an isomerized hop extract containing isoxanthohumol as an active ingredient.
- Isoxanthohumol can be obtained by isomerizing commercially available xanthohumol (for example, available from Apin Chemical Company) or high-purity xanthohumol purified from hops.
- Purification of xanthohumol from a hop can be performed, for example, as follows.
- the dried hops are extracted with ethanol, and the filtrate after filtration is concentrated under reduced pressure.
- the obtained concentrate is subjected to a liquid-liquid partition treatment using hexane and an 85% ethanol aqueous solution to separate an ethanol aqueous layer, and the layer is concentrated under reduced pressure.
- the obtained concentrate is dissolved in chloroform: hexane (5: 2) and passed through a silica gel column, and the fraction eluted with xanthohumol is collected from the obtained fraction.
- the eluate of the fraction thus collected is concentrated under reduced pressure, and the recrystallization method using hexane and ethyl acetate is repeated, whereby purified xanthohumol can be obtained.
- Xanthohumol can be isomerized by heating xanthohumol in the presence of an alkali or magnesium oxide, or by applying xanthohumol to other known methods.
- a specific example of the isomerization treatment is as follows: after dissolving xanthohumol in an alcoholic solvent such as ethanol, adding weakly alcoholic water thereto and heating in the presence thereof (for example, By refluxing at about 93 ° C), xanthohumol can be thermally isomerized into isoxanthohumol.
- the isoxanthohumol obtained by the isomerization treatment can be concentrated or purified by a known method (for example, filtration, concentration under reduced pressure, lyophilization, etc.) as necessary. Isomerized hop extract
- the isomerized hop extract means a hop extract obtained by isomerizing a xanthohumol-containing hop extract obtained from hops by an extraction treatment or the like. That is, isomerized hop extract is basically obtained by obtaining an extract (hop extract) derived from the rubulin part of hops and actively isomerizing it.
- the hop extract can be prepared, for example, by directly extracting or pulverizing a cone or a compact thereof and then subjecting it to an extraction operation.
- Examples of the extraction operation include an extraction method using an ethanol solvent used as a method for preparing a hop extract used for beer brewing.
- the extraction operation other commonly used Hop extraction methods may be employed. For example, (1) a method in which hop cones, crushed material, etc. are immersed in a solvent by cold immersion, hot immersion, or the like; (2) A method in which extraction is performed while heating, stirring, and filtering to obtain an extract. Or (3) a percollation method or the like can also be applied in the extraction operation.
- the crude extract obtained by these extraction operations can be subjected to filtration or centrifugation as necessary to remove solids.
- the obtained liquid may be used as it is as a pop extract, but may be used after the solvent contained therein is distilled off and a part thereof is concentrated or dried.
- the extract obtained after concentration or drying may be further purified by washing with an insoluble solvent, or may be further dissolved or suspended in a suitable solvent.
- the obtained hop extract (liquid) may be used as a dried hop extract extract by conventional means such as drying under reduced pressure and freeze drying.
- Solvents usable in the extraction include, for example, lower alcohols having 1 to 4 carbon atoms such as water, methanol, ethanol, propanol and butanol; lower alkyl esters such as ethyl acetate; ethylene glycol, butylene glycol Glycols such as coal, propylene glycol and glycerin; polar solvents such as ethyl ether, acetone and acetic acid; hydrocarbons such as benzene and hexane; known non-polar solvents such as ethers such as ethyl ether and petroleum ether. Organic solvents. These solvents may be used in combination of two or more.
- an extract containing xanthohumol is obtained using a solvent such as ethanol or water, and the extract is subjected to a supercritical carbon dioxide extraction method to extract the extract contained therein.
- a hop extract containing more xanthohumol can be obtained.
- insolubles may be removed from the hop extract by filtration, or the solvent may be evaporated to dryness by concentration under reduced pressure or the like.
- the hop extract thus obtained contains at least xanthohumol.
- the obtained hop extract may contain, in addition to xanthohumol, a very small amount of its isomer, isoxanthohumol.
- the hop extract non-isomerized bopp extract
- this hop extract is further isomerized to obtain an isomerized hop extract, which is used in the present invention.
- a hop extract containing xanthohumol is dissolved in an alcoholic solvent such as ethanol, then weakly water is added thereto, and the mixture is heated in the presence thereof.
- the hop extract is thermally isomerized by refluxing (for example, at about 92 to 93 ° C.) to obtain an isomerized hop extract containing isoxanthohumol.
- the obtained isomerized hop extract may be concentrated or purified by a known method (for example, filtration, concentration under reduced pressure, lyophilization, etc.) as necessary.
- the isomerized hop extract is obtained by isomerizing the xanthohumol-containing hop extract obtained by extraction with an ethanol-based solvent. More preferably, at this time, the catabolism is performed by heating and refluxing the hop extract in alkaline water.
- the ethanol-based solvent refers to a solvent mainly composed of ethanol or ethanol and water.
- the isomerized hop extract obtained by the isomerization treatment may be directly used for the production of a composition or a food or drink, but it is preferable that the active ingredient in the hop extract is contained at a higher concentration. Get a painting and use it.
- the isomerized hop extract used as an active ingredient of the composition or food or drink according to the present invention has a higher isoxanthohumol concentration than that obtained by simply isomerizing the hop extract. You can have
- a commercially available hop extract extracted by various methods may be obtained and isomerized to be used as an isomerized hop extract, but a commercially available isomerized hop extract may be used as it is. You may.
- the above-mentioned isomerized hop extract containing isoxanthohumol at a high concentration can be obtained by concentrating a normal isomerized hop extract obtained by isomerizing a hop extract extracted from a hop according to a conventional method. It can be easily obtained by adding isoxanthohumol or removing components other than isoxanthohumol.
- hop extract for example, a hop extract obtained by extracting crushed hop cones with ethanol and fractionating the extract by supercritical carbonic acid extraction to increase the xanthohumol content (for example, Xanthohumol-enriched hop product)
- Product name j available from Hops teiner
- Xantho-pure trade name
- the isomerized hop extract used as an active ingredient of the composition or the food or drink according to the present invention contains isoxanthohumol in an amount of 0.05 to 90% by weight. And more preferably 8 to 90% by weight.
- a product containing a high concentration of isoxanthohumol can be produced (that is, without giving excessive bitterness).
- purified isoxanthumol or a hop extract with an increased xanthohumol content eg, Xanthohumol-enriched nop product (trade name), Hopsteiner Isomerized hop extract containing a high concentration of isoxanthohumol, which is obtained by isomerizing products containing about 80% xanthohumol (Xantho-pure (trade name), available from Hopsteiner).
- Xantho-pure trade name
- menopausal osteoporosis The mechanism of onset of menopausal osteoporosis is complex and diverse, and many aspects have not yet been elucidated. There is a limit in explaining the effectiveness of prevention and treatment of postmenopausal osteoporosis based on estrogen agonist activity alone. In fact, in Japan, for example, preparations without estrogen agonist activity are mainly used clinically due to their side effects.
- isoxanthohumol significantly improved the decrease in bone density due to the blockage of estrogen secretion from the ovaries. This suggests that isoxanthohumol may directly or indirectly act on osteoclasts to suppress bone resorption.
- isoxanthohumol was found to have estrogenic activity in in vitro experiments, but was observed in ovariectomized rats in young rats. No uterine hypertrophy was observed even at a dose of at least 1000 times that attaining the effect of improving bone density reduction (see Test 3 in Examples described later). This suggests that isoxanthohumol has a different mechanism from the female hormone 17-estradiol, namely its interaction with estrogen receptor, but its selectivity for bone tissue over uterus. Is estimated to be high.
- the composition or food or drink according to the present invention can suppress and improve the bone density reduction. Alternatively, it can be used for the purpose of prevention. Where possible, the composition or food or drink according to the invention may be used to increase bone density. Therefore, the composition or food according to the present invention can be used for preventing, treating or ameliorating osteoporosis. '
- bone density refers to the amount of minerals such as calcium per fixed volume in the bones of a target mammal, and can be measured by a conventional method.
- conventional methods include a method using X-rays (eg, DXA method, MD method, pQCT method) and a method using ultrasonic waves (eg, QS method). In the present invention, it can be measured, for example, according to Test 4 in Examples described later.
- the method comprises administering or ingesting a mammal with an effective amount of isoxanthohumol or an isomerized hop extract containing isoxanthohumol.
- a method for preventing is provided.
- a method for preventing osteoporosis which comprises administering or ingesting a mammal with an effective amount of isoxanthohumol or isomerized hop extract for preventing, treating or ameliorating. Methods for treating or improving are provided.
- the “effective amount” can be selected according to the dose of isoxanthohumol as described below.
- the order to produce the inhibition or prevention composition for decreasing bone density, isoxanthohumol or c or even of another present invention the use of an isomerized hop extract is provided According to an embodiment, there is provided use of isoxanthohumol or isomerized hop extract for producing a composition for preventing, treating or ameliorating osteoporosis.
- composition according to the present invention comprises isoxanthohumol or isomerized hop extract as an active ingredient.
- composition according to the invention can be administered orally or parenterally.
- Oral preparations include granules, powders, tablets (including sugar-coated tablets), pills, capsules, syrups, emulsions, and suspensions.
- Parenteral preparations include injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections), instillations, and external preparations (eg, nasal preparations, transdermal preparations, ointments) ) And suppositories (eg, rectal suppositories, vaginal suppositories). These preparations can be formulated together with a pharmaceutically acceptable carrier by a method commonly used in the art.
- Pharmaceutically acceptable carriers include excipients, binders, diluents, additives, flavors, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc.
- excipients include excipients, binders, diluents, additives, flavors, buffers, thickeners, colorants, stabilizers, emulsifiers, dispersants, suspending agents, preservatives, etc.
- magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, low-melting-point wax, cocoa yuichi, etc. are used as carriers.
- Bisuhosufone Ichito preparations include preparations Can be manufactured, for example, as follows.
- Oral preparations include, for example, excipients (eg, lactose, sucrose, starch, mannitol), disintegrants (eg, calcium carbonate, calcium carboxymethylcellulose), binders (eg, modified starch, gum arabic, carboxymethylcellulose, polyvinylpyrroli) Don, hydroxypropylcellulose) or a lubricant (eg, talc, magnesium stearate, polyethylene glycol 600) is added to the active ingredient and compression molded, and then, if necessary, taste masking, enteric coating or It can be produced by coating by a method known per se for the purpose of sustainability.
- excipients eg, lactose, sucrose, starch, mannitol
- disintegrants eg, calcium carbonate, calcium carboxymethylcellulose
- binders eg, modified starch, gum arabic, carboxymethylcellulose, polyvinylpyrroli) Don, hydroxypropylcellulose
- a lubricant eg
- the coating agent examples include ethylcellulose, hydroxymethylcellulose, polyoxyethylene glycol, cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate and Eudragit (Rome's Doy, methacrylic acid / acrylic acid copolymer). , Gelatin, Pullulan or the like can be used.
- Injectables are prepared by dispersing the active ingredient in a dispersant (for example, Tween 80 (manufactured by Atlas Pada Co., USA), HCO 60 (manufactured by Nikko Chemicals), polyethylene glycol, carboxymethyl cellulose, sodium alginate, etc.) , Preservatives (eg, methyl paraben, propyl paraben, benzyl alcohol, chlorobutanol, phenol), tonicity agents (eg, sodium chloride, glycerin, sorbitol, glucose, invert sugar), and aqueous solvents (eg, Manufactured by dissolving, suspending or emulsifying in distilled water, physiological saline, Ringer's solution, etc.
- a dispersant for example, Tween 80 (manufactured by Atlas Pada Co., USA), HCO 60 (manufactured by Nikko Chemicals), polyethylene glycol, carboxymethyl cellulose, sodium alginate
- oily solvents eg, vegetable oils such as olive oil, sesame oil, cottonseed oil, corn oil, and propylene glycol.
- additives such as a solubilizing agent (for example, sodium salicylate, sodium acetate), a stabilizer (for example, human serum albumin), and a soothing agent (for example, benzalkonidum chloride, proforce hydrochloride) are added. It may be added.
- compositions include a pH regulator (for example, carbonic acid, phosphoric acid, citric acid, hydrochloric acid, sodium hydroxide), a preservative (for example, paraoxybenzoic acid esters, chlorobutanol, benzalkonidium chloride). ) May be further included.
- a pH regulator for example, carbonic acid, phosphoric acid, citric acid, hydrochloric acid, sodium hydroxide
- a preservative for example, paraoxybenzoic acid esters, chlorobutanol, benzalkonidium chloride.
- Suppositories can be prepared by preparing the active ingredient as an oily or aqueous solid, semi-solid or liquid composition.
- an oily or aqueous base can be used.
- the oleaginous base used in the composition includes glycerides of higher fatty acids (eg, cocoa butter, witepsol (manufactured by Dynamite Nobel)), intermediate fatty acids (eg, miglyols (manufactured by Dynamite Nobel)), or Vegetable oils (eg, sesame oil, soybean oil, cottonseed oil).
- Aqueous bases include polyethylene glycols, Propylene glycol.
- Examples of the aqueous gel base include natural gums, cellulose derivatives, vinyl polymers, and acrylic acid polymers.
- the food or drink according to the present invention contains the active ingredient according to the present invention in an effective amount.
- the active ingredient according to the present invention can be blended with the food or drink as it is or in the form of the composition described above. More specifically, the food or drink according to the present invention is prepared as a food or drink by directly or isomerizing the active ingredient according to the present invention or the above-mentioned ground hops or extract, various proteins, sugars, fats, trace amounts It may be prepared by further blending elements, vitamins, etc., or added to general food and drink.
- “food and drink” is not limited to pharmaceuticals, and is not particularly limited as long as it can be ingested by mammals, and may be in any form of liquid, semi-liquid or solid It may be.
- foods and beverages include, for example, beverages.
- Foods and beverages also include those classified as health foods, functional foods, foods for specified health uses, and foods for the sick.
- “food and drink” can be used to include feed when used for mammals other than humans.
- the active ingredient in the present invention has a bone loss suppressing or preventing action.
- the present invention is applied to health foods and functional foods taken as daily food supplements, foods containing one or more kinds of minerals such as calcium and magnesium, and vitamins such as vitamin K.
- a food or drink can be provided which has functions of preventing, treating and improving the occurrence of osteoporosis, and preventing the osteoporosis spare group from shifting to osteoporosis.
- the food or drink according to the present invention is a food or drink suitable for a consumer who wants to increase bone density or prevent its decrease, or a food or drink suitable for a consumer concerned about bone health, that is, a so-called specific Health food, can be provided as
- ⁇ food for specified health use '' as used herein means that when manufacturing or selling food for the purpose of suppressing or preventing loss of bone density, each country may be subject to any legal restrictions in terms of health.
- a certain food or drink is a food or drink suitable for a consumer who wants to increase bone density or prevent its decrease, or a food or drink suitable for a consumer concerned about bone health, that is, a so-called specific Health food.
- foods and drinks include carbohydrate-containing foods and drinks such as rice, rice, bread and pasta; Western confectionery such as cookies and cakes; Japanese confectionery such as buns and yokan; candy and gums , Yogurt, pudding, and other confections such as frozen desserts and frozen desserts; various youth, soft drinks, milk drinks, tea drinks, functional drinks, nutritional supplements, non-alcohol beers, etc .; Beverages: processed products using eggs, fish and shellfish (squid, yuko, shellfish, eel, etc.) Processed products of livestock meat (including offal such as levers) (including delicacies).
- the food or drink is a non-cereal-hop fermented food or drink.
- non-food-hop fermented food or drink refers to a food or drink that does not contain a fermentation component (eg, beer, low-malt beer) obtained by performing fermentation using at least hop and food.
- the non-cereal-hop fermented food / beverage product refers to a food / beverage product other than a fermented beverage containing hops as a raw material such as beer and low-malt beer.
- the food or drink includes tea drinks, milk drinks, and yogurt.
- the food or drink is a beverage.
- tea drink refers to a drink for infusing tea leaves (tea leaves), which are evergreen trees of the genus Periflorida, or leaves or grains of plants other than tea trees, and is fermented tea, semi-fermented tea, and unfermented tea. Both types of tea are included.
- tea beverages include Japanese tea (eg, green tea, barley tea), black tea, herbal tea (eg, jasmine tea), Chinese tea (eg, Chinese green tea, oolong tea), and Hojicha.
- a milk beverage refers to a beverage made from raw milk, milk, or the like, or a food produced using these as a raw material.
- milk and other raw materials for example, nutrient-enriched milk, flavored milk, and sugar-decomposed milk
- processed milk such as milk as a raw material.
- Yogurt includes hard, soft and drink types, as well as processed yogurt products made from yogurt.
- the active ingredient or hop bitterness is It is preferable to use it in a range that does not affect the taste of the rice cake, or to take measures to mask the bitter taste.
- foods and drinks derived from a hop such as a beer, a non-alcoholic beer, and a low-malt beer may already contain a certain amount or more of the active ingredient of the present invention. That is, such known isoxanthohumol-containing foods and drinks are not simply foods to which a pop component is added, but foods and drinks produced through a process of isomerization of a pop component. In the case of such foods and drinks, they can be used as they are as foods and drinks according to the present invention. Further, by blending isoxanthohumol or an extract containing the same or isomerized hop extract with these foods and drinks. The desired effect can be further enhanced or the effective intake can be reduced.
- isoxanthohumol-containing food and drink examples include beer.
- the content of isoxanthohumol in beer is, for example, from 0.04 to 3.4 mg / L as described above, but in beer, isohumulone, which is a bitter component, and has estrogenic activity. It also contains prenylnaringenin.
- prenylnaringenin it is known that the content of 8-prenylnaringenin in beer varies widely from 1/6 to 1/3 of the isoxanthohumol content (J. Chromatogr. A 832, 97-107 1999).
- hop extract in an isomerized form than to use purified isoxanthohumol from the viewpoint of cost.
- isomerized hop extract when using isomerized hop extract in foods and drinks, it is desirable to consider the sensory points due to bitterness caused by isohumulones and the like. In this case, increase the hop extract or isoxanthohumol content with increased xanthohumol content. It is preferred that the content of isofumone in the food or drink relative to isoxanthohumol be relatively reduced by using the increased isomerized hop extract. Alternatively, the amount of hop, hop extract, or isomerized hop extract may be increased after masking the bitter component.
- purified isoxanthohumol may be added to the food production process or final product, or isomerization may occur during the production process. If there is a step that causes a reaction, purified xanthohumol may be added before the step.
- composition or food or drink according to the present invention is a hop extract component or a derivative thereof that has been ingested by humans as food or drink for many years, and therefore has low toxicity and is useful in mammals (eg, humans, mice, rats, rabbits, Can be safely used for dogs, cats, cats, dogs, horses, bush, monkeys, etc.).
- mammals eg, humans, mice, rats, rabbits, Can be safely used for dogs, cats, cats, dogs, horses, bush, monkeys, etc.
- the composition according to the present invention is used for the purpose of increasing the bone density of a mammal to be administered or suppressing, improving or preventing the decrease in the bone density (preferably, for the purpose of preventing, treating or improving osteoporosis)
- the dose can be determined depending on the recipient, age and weight of the recipient, symptoms, administration time, dosage form, administration method, drug combination, and the like.
- the active ingredient according to the present invention is orally administered as a medicament
- 10 mgZkg: body weight, preferably in the range of 0.01 to 1 OmgZkg body weight can be administered once or several times daily in divided dose units.
- the amount per adult is 5 mg / kg body weight per day as the amount of isoxanthohumol (30 mg per day per adult per day).
- Amount can be administered in the following range, preferably in the range of lmg ⁇ kg body weight 'day or less.
- the composition according to the present invention has an isoxanthohumol intake per adult ranging from 0.003 to 5 mgZkg body weight per day (per adult per 60 kg body weight per day). Isoxanthohumol intake in the range of 0.2-300 mg). More preferred In other words, the lower limit of the isoxanthohumol intake is 0.013 mg / kg body weight per day as the intake per adult (0 kg per adult per 60 kg body weight per day). 8 mg) or more, and more preferably 0.02 mg / kg body weight per day (1.2 mg per day for an adult weighing 60 kg per person).
- the food or drink according to the present invention has an isoxanthohumol intake per adult ranging from 0.003 to 0.5 rng / kg body weight per day (one adult weighing 60 kg). Isoxanthohumol so that the daily intake of isoxanthohumol is in the range of 0.2 to 30 mg). More preferably, the lower limit of the isoxanthohumol intake is 0.013 mg / kg body weight per day as an intake per adult (0. 8 mg) or more, and more preferably 0.02 mg / kg body weight per day (1.2 mg per day for an adult with a body weight of 60 ⁇ per day).
- the lower limit of isoxanthohumol intake is 0.00 SmgZkg body weight per day as an adult per person ((0,0 mg per adult per 60 kg body weight per day. 2 mg) is equivalent to administering 10 ml / kg of a test reagent with a concentration of 2 mg of isoxanthohumol, which was confirmed to be effective in Experiments 4 and 5 in the Examples described below.
- the value obtained by converting the ratio of the body surface area of rat to that of the human is also obtained. 0 ⁇ 02 mg / kg body weight ⁇ day ((The daily intake per adult of 60 kg body weight is 1.2 mg).
- the upper limit of isoxanthohumol intake is 0.5 mg / kg body weight per day for an adult ((3 adults per 60 kg body weight per day).
- Omg) or less is based on the degree of dissolution of isoxanthohumol and eating experience, and a value higher than this does not deny the effect of suppressing bone density loss. Therefore, if possible, the food or drink may contain isoxanthohumol in an amount equal to or greater than the upper limit.
- the food or drink has an isoxanthohumol intake per serving of 0.2 to 30 mg, more preferably 0.8 to 30 mg, and still more preferably 1.2 to 3 Omg. It contains isoxanthohumol in such an amount as follows.
- the amount of isoxanthohumol taken at one time refers to the amount of isoxanthohumol contained in foods and drinks that a human consumes during eating behavior. Therefore, if there are foods and drinks that are supposed to be consumed by humans in a single eating behavior, “the amount of isoxanthohumol per serving” is the amount of isoxanthohumol contained in such foods and drinks. Equivalent to the amount of the mall.
- the form of foods and drinks that humans expect to consume in a single eating behavior depends on the physical factors such as weight, age, gender, physical fitness, health status, etc., of the subjects who are expected to consume the foods and drinks. Can be set as appropriate by considering the expected environment or climate. For example, such food and beverage forms include beverages enclosed in containers in units ranging from 100 to 50 Oml (preferably 100 to 350 ml).
- the isoxanthohumol intake (0.2 to 3 Omg) Isoxanthohumol. Therefore, the concentration of isoxanthohumol in this beverage ranges from 2 to 300 mg / L.
- the 35 Oml beverage contains the isoxanthohumol intake (0.2 to 30 mg). ))
- the beverage will have a concentration of isoxanthohumol in the range of 0.5 ⁇ to 85.7 mg / L.
- Beer Korean Beer (Kirin Lager Beer (trade name), manufactured by Kirin Brewery Co., Ltd. (Japan)) (hereinafter abbreviated as "beer")
- powdery hop extract Xanthohumol Enriched Product (trade name) containing a large amount of xanthohumol )
- Xantho-pure trade name, both manufactured by Hopsteiner
- HP LC analysis was confirmed by HP LC analysis and nuclear magnetic resonance (NMR) spectroscopy.
- HP LC conditions for purity confirmation were as follows:
- Hop extract (Xanthohumol Enriched Product (trade name)) 1 was added to water 11 ⁇ , and the mixture was boiled in a autoclave at 100 ° C for 120 minutes to be isomerized. After cooling to room temperature, the supernatant was filtered using filter paper to obtain a filtrate. Then, 800 ml of the filtrate was extracted using 1000 ml of Jetil ether. The jetilayer layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Thereafter, 2 Oml of ethyl acetate was added, and the mixture was again dried over anhydrous sodium sulfate and concentrated under reduced pressure to about 1 ml.
- the purity of the purified isoxanthohumol was confirmed by HPLC analysis and nuclear magnetic resonance (NMR) spectrum measurement in the same manner as in the case of the above-mentioned purification from beer.
- HP LC analysis confirmed that the purity of isoxanthohumol was greater than 98%.
- Example C Formulation preparation
- the following components were finely powdered, sufficiently stirred so as to form a uniform mixture, and then 0.2 g each was filled in a pullulan capsule or a gelatin capsule to prepare a capsule preparation.
- the estrogen activity of the test substance was measured using the cell proliferation of MCF-7 cells derived from estrogen-sensitive human breast cancer as an index.
- the cell line used expressed estrogen receptor, and enhanced cell proliferation was observed in the presence of estrogen-like substances. Therefore, estrogen activity was measured by measuring cell proliferation of this cell line using Cell Counting Kit (manufactured by Dojindo Laboratories).
- the measurement of cell proliferation of MCF_7 cells using the Cell Counting Kit was performed using the WST-1 reagent [2- (4,5-dimethylthiazol-1-yl)]-2,5 —The formazan generated from diphenyltetrazolium, monosodium salt (2- (4,5-dimethylchiazol-2-yl) -2,5-diphenyltetrazolium, monosodiuin salt) j is converted to a microplate reader (SOFTmax (Molecular Devices) )) was used to measure the absorbance at 450 nm.
- WST-1 reagent [2- (4,5-dimethylthiazol-1-yl)]-2,5 —The formazan generated from diphenyltetrazolium, monosodium salt (2- (4,5-dimethylchiazol-2-yl) -2,5-diphenyltetrazolium, monosodiuin salt) j is converted to a microplate reader (SOFTmax (Molecular Devices
- Dextran-Coated Charcoal contains 10% fetal calf serum (Gibco), which has been removed by adsorbing endogenous raw I steroid, and further contains penicillin and streptomycin (each of which is included).
- fetal calf serum Gibco
- penicillin and streptomycin each of which is included.
- 10,000 units, 1 mg / ml N Gibco, 0.1 mM non-essential amino acid (Gibco), ImM sodium pyruvate (Gibco), and l / g / ml insulin (human recombinant) MCF-7 cells were pre-cultured for 3 days using a DMEM medium containing 27.5 USP unit / mg: (Sigma)).
- a cell suspension having a concentration of 8 ⁇ 1 OellsZml of the MCF-7 cells was prepared, and this was inoculated on a 96-well plate at 100-well.
- the medium in the wells was replaced with a medium containing the test substance 0.1% ( ⁇ / ⁇ ) dissolved in dimethyl sulfoxide, and the culture was continued.
- the medium in the gel was replaced again with a fresh medium containing the test substance, and on day 7 of culture, cell proliferation was measured using the Cell Counting Kit.
- estradiol manufactured by Sigma
- dimethyl sulfoxide dimethyl sulfoxide
- the beer was degassed, applied to an ENVI-18 column (10 g, 60 ml, manufactured by Supelco) and eluted sequentially with 20%, 50%, 80% aqueous methanol and 180 ml of methanol, respectively.
- the estrogen activity of each fraction was measured according to the method described above. As a result, the activity was confirmed in each of the eluted fractions of 80% methanol and methanol.
- n-hexane 1: 7, 1: 4 and ethyl acetate were eluted in this order.
- HP LC conditions were as follows:
- the mass (MS) spectrum of the substance contained in Fr 8 was measured using a mass spectrometer (DX303 manufactured by JEOL Ltd.) according to the EI-MS method. At that time, ions were observed at mZz 354. This was consistent with the standard spectral pattern of isoxanthohumol.
- 1 ⁇ 8 5111 was dissolved in 600/1 heavy dimethyl sulfoxide, and 1H-NMR, 13C-NMR ⁇ and 1H-NMR were measured using a nuclear magnetic resonance (NMR) spectrometer (UNITY plus 500 type (manufactured by Varian)). Measurement of NOE SY-1D confirmed that the active ingredient of Fr8 was isoxanthohumol.
- the analyzer used was an HP LC (HP1100 (Agilent)) connected to a triple-stage mass spectrometer (MSZMS) (Quattro Ultima (Micromass)).
- HPLC HP1100 (Agilent)
- MSZMS triple-stage mass spectrometer
- Quattro Ultima Quattro Ultima (Micromass)
- the conditions of the mass spectrometer were such that the ionization was electrospray ionization (E S 1_), the precursor ion was 338.3, the product ion was 218.8, the Cone voltage was 80 V, and the Collision energy was 20 eV.
- FrI O contained a high concentration of 8-prenylnaringenin.
- the analyzer used was a HPLC (HP1100 (manufactured by Agilent)) connected to a triple-stage mass spectrometer (MS MS) (Quattro Ultima (manufactured by Micromass)).
- HPLC conditions at this time were as follows: Moving bed: Liquid A (acetonitrile), Liquid B (distilled water), and Liquid A 55% ⁇
- the mass spectrometer conditions were electrospray ionization (ESI-1) for ionization, and both compounds were simultaneously quantitatively analyzed in MRM mode.
- Quantitative ions and ionization conditions were as follows: for isoxanthohumol, precursor ion 352.8, product ion 232.8, Cone voltage 80 V, and Collision energy 18 eV.
- the precursor ion was 338 ⁇ 3
- the product ion was 218.8
- the Cone voltage was 80 V
- the Collision energy was 20 eV.
- Estrogenic activities of purified isoxanthohumol and chemically synthesized 8-prenylnaringenin were measured in the same manner as in Test 1. However, at this time, the concentration of the test substance in the medium for culturing MCF-7 cells was set as follows.
- Isoxanthohumol it said medium concentration, 1 ⁇ 0x l 0- 5, 1. 0x 10 ⁇ 1. 0 ⁇ 10- 7, 1 ⁇ Ox l O- 8, 1. 0x l 0_ 9, and 1 . 0 X 10 - 1 ° was added to a mo 1 / L.
- Isoxanthohumol and 8-prenylnaringenin are both Gen activity. When these activities were compared to estradiol, the active is about 10 5 times the Isoki Santofumoru, 8-prenylnaringenin in one 10 2 Baidea.
- Test 3 Evaluation of estrogen activity in vivo
- the rats used were prepared as follows. First, 20-day-old Wistar female rats (available from Nippon Charles River Co., Ltd.) were selected so that the weight difference of each animal was within 10% of the average body weight, and then randomly selected as 6 animals per group. The animals were divided into groups and bred with water and AI N-76A (Clea Japan) freely.
- isoxanthohumol or 8-prenylnaringenine is administered at a dose of 1, 5 or 25 mg once / day for 3 days at a dose of 10 ml / kg per day for 3 days.
- a solvent peanut oil
- 17 ⁇ -estradiol was orally administered at a dose of 400 zg / k day.
- the uterus was removed from the rat, and its weight was weighed to measure the in vivo estrogen activity.
- Isoxanthohumol unlike estradiol or 8-prenylnaringen, was found to have no, or only very weak, in vivo estrogenic activity on young rats.
- the ovaries of a 9-week-old female SD rat were excised, and from the next day, the test substance was administered by gavage at a gastric volume of 1 O ml Zkg once daily for 28 days using an oral probe. .
- the control group and the sham operation group were orally administered with a 0.8% aqueous ethanol solution in the same manner. As a positive control, 17? -Estradiol was used.
- Beer domestic Pilsuna beer
- isoxanthohumol contains 2.1 mg / g of isoxanthohumol and 43 g of 8-prenylnaringenin.
- this was once freeze-dried and then dissolved in water to remove ethanol and used as a test substance in the test.
- Isoxanthohumol is prepared by dissolving isoxanthohumol in a 0.8% aqueous ethanol solution so that it will have the same, 5-fold, and 20-fold concentration as that contained in beer. Was.
- 'Xanthohumol an isomer of isoxanthohumol (ADin chemical A liquid diluted with water, prepared so that xanthohumol has the same concentration (2.1 mg / L) as isoxanthohumol contained in beer.
- Bone density was measured by collecting rat femurs and measuring the trabecular bone density at the distal end using a PQCT (Peripheral Quantitative Computed Tomography) bone density analyzer (XCT-960A (Norland Stratech). )). The results were as shown in FIG. 5 and FIG.
- ovariectomized group trabecular bone density in the femur was reduced, but was significantly improved by beer and isoxanthohumol administration. No such improvement was observed for 8-prenylnaringenin, which is considered to have the highest contribution of estrogen activity in beer.
- isoarsenic acid containing xanthohumol disohumulones bone resorption inhibiting activities have already been reported by the Pit Formation Assay, but no activity similar to isoxanthohumol was observed in these.
- the bilateral ovaries of a 9-week-old female SD rat were excised, and from the next day, the test solution was intragastrically orally administered at a dose of 1 Oml Zkg using an oral sonde once a day for 28 days. Water was orally administered to the control group and the sham operation group in the same manner. As a positive control, 17-estradiol dissolved in peanut oil was used and administered subcutaneously in an amount of 10 1gZkg / day.
- Barley tea extracted in the same manner as in Example D, but not containing isoxanthohumol, Barley tea containing isoxanthohumol at concentrations of 2 mg / L, 10 mg / L, and 50 mg / L, respectively.
- the measurement of the bone density was performed in the same manner as in Test 4 described above.
- the cancellous bone density in the femur of the ovariectomized group (OVX) was lower than that in the sham-operated group, but the bone density of the group that received the drink containing isoxanthohumol was lower than that of the control that received water. Significantly higher than the group, an improvement effect on bone density reduction was observed. On the other hand, in the case of a beverage containing no isoxanthohumol, no improvement effect on bone density reduction was observed.
- Green tea is generally considered to contain a large amount of tea-powered techin, which is known to suppress the activity of osteoclasts involved in bone resorption (Biocheiu Biophys Res Commun 292 (1), 94-101 (2002) )).
- tea-powered techin which is known to suppress the activity of osteoclasts involved in bone resorption.
- no effect of suppressing osteopenia in ovariectomized rats was observed. Therefore, even in the case of green tea, the improvement effect on bone density reduction was recognized only by adding isoxanthohumol (Fig. 8).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dairy Products (AREA)
- Tea And Coffee (AREA)
- Pyrane Compounds (AREA)
- Non-Alcoholic Beverages (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE602004016486T DE602004016486D1 (de) | 2003-04-08 | 2004-04-08 | Zusammensetzung zur hemmung oder prävention der verringerung der knochendichte |
JP2005505319A JPWO2004089359A1 (ja) | 2003-04-08 | 2004-04-08 | 骨密度減少の抑制または予防用組成物および飲食品 |
US10/552,447 US20070059393A1 (en) | 2003-04-08 | 2004-04-08 | Composition for inhibition or prevention of bone density |
EP04726643A EP1618875B1 (en) | 2003-04-08 | 2004-04-08 | Composition for inhibition or prevention of bone density lowering |
US12/472,282 US20100105766A1 (en) | 2003-04-08 | 2009-05-26 | Composition for inhibition or prevention of bone density reduction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-104515 | 2003-04-08 | ||
JP2003104515 | 2003-04-08 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/472,282 Continuation US20100105766A1 (en) | 2003-04-08 | 2009-05-26 | Composition for inhibition or prevention of bone density reduction |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004089359A1 true WO2004089359A1 (ja) | 2004-10-21 |
Family
ID=33156857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/005087 WO2004089359A1 (ja) | 2003-04-08 | 2004-04-08 | 骨密度減少の抑制または予防用組成物および飲食品 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20070059393A1 (ja) |
EP (1) | EP1618875B1 (ja) |
JP (1) | JPWO2004089359A1 (ja) |
CN (1) | CN1791393A (ja) |
AT (1) | ATE407667T1 (ja) |
DE (1) | DE602004016486D1 (ja) |
WO (1) | WO2004089359A1 (ja) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1909584A2 (en) * | 2005-07-29 | 2008-04-16 | Bioactives, Inc. | Prenylflavonoid formulations |
JP2008532558A (ja) * | 2005-03-25 | 2008-08-21 | ウニベルズィタイト・ヘント | フラボノイド類の酵素的脱メチル化 |
JP2013063940A (ja) * | 2011-09-20 | 2013-04-11 | Nippon Yakuhin Kaihatsu Kk | 骨粗鬆症予防または改善剤 |
JP2015522648A (ja) * | 2012-07-26 | 2015-08-06 | テーアー−クサン アーゲー | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
WO2019131697A1 (ja) * | 2017-12-27 | 2019-07-04 | サントリーホールディングス株式会社 | 飲料およびその製造方法 |
WO2020031953A1 (ja) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | 微生物増殖抑制剤、微生物汚染防止方法、及び、飲料 |
WO2020144897A1 (ja) * | 2019-01-11 | 2020-07-16 | サントリーホールディングス株式会社 | イソキサントフモールを含有する組成物の製造方法 |
WO2020145282A1 (ja) * | 2019-01-11 | 2020-07-16 | サントリーホールディングス株式会社 | イソキサントフモールを含有する組成物の製造方法 |
JP2020182387A (ja) * | 2019-04-26 | 2020-11-12 | サントリーホールディングス株式会社 | ビールテイスト飲料 |
WO2020230801A1 (ja) * | 2019-05-15 | 2020-11-19 | サントリーホールディングス株式会社 | 容器詰飲料、及び、イソキサントフモールの保存安定性を高める方法 |
WO2021131568A1 (ja) * | 2019-12-25 | 2021-07-01 | サントリーホールディングス株式会社 | 身体活動量低下の抑制又は改善用組成物 |
JPWO2020031952A1 (ja) * | 2018-08-10 | 2021-08-26 | サントリーホールディングス株式会社 | 血糖値上昇抑制用組成物及び血糖値上昇抑制方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110223642A1 (en) * | 2010-03-11 | 2011-09-15 | John Paul Maye | Method for inhibiting bacteria growth during ethanol fermentation |
EP2392325A1 (en) * | 2010-06-04 | 2011-12-07 | Universitätsklinikum Münster | Compounds for the prevention and/or treatment of osteoarthrosis |
KR101323150B1 (ko) * | 2011-04-25 | 2013-10-30 | 충남대학교산학협력단 | 잔토휴몰을 함유하는 골다공증 예방 및 치료용 조성물 |
CN103371989A (zh) * | 2012-04-24 | 2013-10-30 | 华东师范大学 | 黄腐酚在制备抑制破骨细胞分化和蚀骨功能的预防和/或治疗药物中的应用 |
US20210298332A1 (en) * | 2018-08-10 | 2021-09-30 | Suntory Holdings Limited | Agent for suppressing heat-resistant acidophilic bacteria, method for preventing contamination with heat-resistant acidophilic bacteria, and beverage |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07285856A (ja) * | 1994-04-21 | 1995-10-31 | Hoechst Japan Ltd | 骨粗鬆症治療剤 |
JPH07330594A (ja) * | 1994-04-12 | 1995-12-19 | Hoechst Japan Ltd | 骨粗鬆症治療剤 |
WO2003014287A1 (de) * | 2001-08-10 | 2003-02-20 | Dr. Willmar Schwabe Gmbh & Co. | Hopfenextrakte, verfahren zu ihrer herstellung und verwendung |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3794744A (en) * | 1972-05-10 | 1974-02-26 | White Tomkins Ltd | Purification of hop extracts |
NZ245989A (en) * | 1992-02-28 | 1995-02-24 | Lilly Industries Ltd | Anthraquinone derivatives and pharmaceutical compositions |
WO2001003687A2 (en) * | 1999-07-13 | 2001-01-18 | Cedars-Sinai Medical Center | Method and compositions for inhibiting biosynthesis or bioactivity of endogenous steroid sex hormones in humans |
WO2001076614A1 (fr) * | 2000-04-10 | 2001-10-18 | Takara Bio Inc. | Remedes |
US20030203857A1 (en) * | 2000-04-11 | 2003-10-30 | Hiromu Ohnogi | Remedies |
FR2823672B1 (fr) * | 2001-04-23 | 2004-03-12 | Berkem Sa | Extraits de houblon et leur utilisation dans la preparation d'un medicament ayant des proprietes oestrogenes |
DE10315025A1 (de) * | 2003-04-02 | 2004-10-14 | Bioplanta Arzneimittel Gmbh | Wirkstoffkombination von ω3-fettsäurehaltigen Ölen mit polyphenolhaltigen Pflanzenextrakten und deren Verwendung |
-
2004
- 2004-04-08 WO PCT/JP2004/005087 patent/WO2004089359A1/ja active IP Right Grant
- 2004-04-08 CN CNA2004800137846A patent/CN1791393A/zh active Pending
- 2004-04-08 DE DE602004016486T patent/DE602004016486D1/de not_active Expired - Lifetime
- 2004-04-08 AT AT04726643T patent/ATE407667T1/de not_active IP Right Cessation
- 2004-04-08 JP JP2005505319A patent/JPWO2004089359A1/ja active Pending
- 2004-04-08 US US10/552,447 patent/US20070059393A1/en not_active Abandoned
- 2004-04-08 EP EP04726643A patent/EP1618875B1/en not_active Expired - Lifetime
-
2009
- 2009-05-26 US US12/472,282 patent/US20100105766A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07330594A (ja) * | 1994-04-12 | 1995-12-19 | Hoechst Japan Ltd | 骨粗鬆症治療剤 |
JPH07285856A (ja) * | 1994-04-21 | 1995-10-31 | Hoechst Japan Ltd | 骨粗鬆症治療剤 |
WO2003014287A1 (de) * | 2001-08-10 | 2003-02-20 | Dr. Willmar Schwabe Gmbh & Co. | Hopfenextrakte, verfahren zu ihrer herstellung und verwendung |
Non-Patent Citations (2)
Title |
---|
STEVENS J.F. ET AL.: "Fate of xanthohumol and related prenylflavonoids from hops to beer", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 47, no. 6, 1999, pages 2421 - 2428, XP002980501 * |
TATSUTSUMI O. ET AL.: "Kotsusoshosho model rat ni okeru beer ni fukumareru hop yurai seibun no honemitsudo gensho yokusei koka", DAI 57 KAI THE JAPANESE SOCIETY OF NUTRITION AND FOOD SCIENCE TAIKAI KOEN YOSHISHU, 1 April 2003 (2003-04-01), pages 203, XP002984703 * |
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008532558A (ja) * | 2005-03-25 | 2008-08-21 | ウニベルズィタイト・ヘント | フラボノイド類の酵素的脱メチル化 |
US8709764B2 (en) | 2005-03-25 | 2014-04-29 | Universiteit Gent | Enzymatic demethylation of flavonoids |
EP1909584A2 (en) * | 2005-07-29 | 2008-04-16 | Bioactives, Inc. | Prenylflavonoid formulations |
EP1909584A4 (en) * | 2005-07-29 | 2010-07-07 | Bioactives Inc | PRENYLFLAVONOID FORMULATIONS |
JP2013063940A (ja) * | 2011-09-20 | 2013-04-11 | Nippon Yakuhin Kaihatsu Kk | 骨粗鬆症予防または改善剤 |
US9782362B2 (en) | 2012-07-26 | 2017-10-10 | Ta-Xan Ag | Uses of compositions containing a roasted extract and xanthohumol |
JP2018087195A (ja) * | 2012-07-26 | 2018-06-07 | テーアー−クサン アーゲー | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2020090501A (ja) * | 2012-07-26 | 2020-06-11 | アントニオ・アルカイニAntonio Arcaini | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2022104969A (ja) * | 2012-07-26 | 2022-07-12 | アントニオ・アルカイニ | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JP2015522648A (ja) * | 2012-07-26 | 2015-08-06 | テーアー−クサン アーゲー | 焙煎抽出物およびキサントフモールを含む組成物の使用 |
JPWO2019131697A1 (ja) * | 2017-12-27 | 2020-12-10 | サントリーホールディングス株式会社 | 飲料およびその製造方法 |
WO2019131697A1 (ja) * | 2017-12-27 | 2019-07-04 | サントリーホールディングス株式会社 | 飲料およびその製造方法 |
JP7218304B2 (ja) | 2017-12-27 | 2023-02-06 | サントリーホールディングス株式会社 | 飲料およびその製造方法 |
JPWO2020031953A1 (ja) * | 2018-08-10 | 2021-08-10 | サントリーホールディングス株式会社 | 微生物増殖抑制剤、微生物汚染防止方法、及び、飲料 |
JPWO2020031952A1 (ja) * | 2018-08-10 | 2021-08-26 | サントリーホールディングス株式会社 | 血糖値上昇抑制用組成物及び血糖値上昇抑制方法 |
WO2020031953A1 (ja) * | 2018-08-10 | 2020-02-13 | サントリーホールディングス株式会社 | 微生物増殖抑制剤、微生物汚染防止方法、及び、飲料 |
WO2020145282A1 (ja) * | 2019-01-11 | 2020-07-16 | サントリーホールディングス株式会社 | イソキサントフモールを含有する組成物の製造方法 |
JPWO2020145282A1 (ja) * | 2019-01-11 | 2021-11-25 | サントリーホールディングス株式会社 | イソキサントフモールを含有する組成物の製造方法 |
WO2020144897A1 (ja) * | 2019-01-11 | 2020-07-16 | サントリーホールディングス株式会社 | イソキサントフモールを含有する組成物の製造方法 |
JP2020182387A (ja) * | 2019-04-26 | 2020-11-12 | サントリーホールディングス株式会社 | ビールテイスト飲料 |
JP7212576B2 (ja) | 2019-04-26 | 2023-01-25 | サントリーホールディングス株式会社 | ビールテイスト飲料 |
WO2020230801A1 (ja) * | 2019-05-15 | 2020-11-19 | サントリーホールディングス株式会社 | 容器詰飲料、及び、イソキサントフモールの保存安定性を高める方法 |
JPWO2020230801A1 (ja) * | 2019-05-15 | 2020-11-19 | ||
WO2021131568A1 (ja) * | 2019-12-25 | 2021-07-01 | サントリーホールディングス株式会社 | 身体活動量低下の抑制又は改善用組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP1618875B1 (en) | 2008-09-10 |
JPWO2004089359A1 (ja) | 2006-07-06 |
DE602004016486D1 (de) | 2008-10-23 |
EP1618875A1 (en) | 2006-01-25 |
US20070059393A1 (en) | 2007-03-15 |
CN1791393A (zh) | 2006-06-21 |
EP1618875A4 (en) | 2006-05-24 |
US20100105766A1 (en) | 2010-04-29 |
ATE407667T1 (de) | 2008-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100105766A1 (en) | Composition for inhibition or prevention of bone density reduction | |
TWI242437B (en) | Composition for reducing low density lipoprotein cholesterol concentration | |
CA2854281C (en) | A muscle atrophy inhibitor | |
JP2006306800A (ja) | ファルネソイドx受容体活性化剤 | |
JP4684556B2 (ja) | Sdgの製法およびその配合飲食物 | |
JP4974116B2 (ja) | ビワ葉抽出物を含有する飲食品及び医薬品 | |
US20040116498A1 (en) | Regulations of lipids and/or bone density and compositions therefor | |
JP2008222656A (ja) | 肥満改善および予防用組成物ならびに健康食品 | |
KR101820096B1 (ko) | 콩 발아배아 추출물을 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물 | |
KR102080410B1 (ko) | 엘더베리 추출물을 유효성분으로 함유하는 남성 갱년기 증후군의 예방, 치료 또는 개선용 조성물 | |
KR100874778B1 (ko) | 발효청국장 추출물을 포함하는 갱년기 질환의 예방 및치료용 조성물 | |
AU2004206156B2 (en) | Blood pressure-lowering agent, vascular flexibility-improving agent and foods having these functions imparted thereto | |
JP6131275B2 (ja) | Igf−1産生促進剤 | |
JP2003095941A (ja) | 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物 | |
KR20030039629A (ko) | 폴리아세틸렌계 화합물을 함유하는 식품 소재 | |
KR20240037489A (ko) | 결명자 추출물을 이용한 장내 미생물 군총 개선용 조성물과 대장암에 대한 항암용 조성물 | |
KR20110076053A (ko) | 스페니쉬 오레가노 추출물 또는 여름세이보리 추출물을 유효성분으로 함유하는 대사성 질환 예방 및 치료용 조성물 | |
US20080161385A1 (en) | Composition Inhibiting Sex Hormone-Binding Globulin | |
WO2006068117A1 (ja) | 腎障害予防剤およびその機能が付与された食品 | |
JP2006290882A (ja) | 抗肥満剤 | |
WO2006022314A1 (ja) | コレステロール代謝制御剤、それを含有する飲食品、食品添加物及び医薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005505319 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004726643 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048137846 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2004726643 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007059393 Country of ref document: US Ref document number: 10552447 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10552447 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2004726643 Country of ref document: EP |